R&D Insights: How Alkermes plc and Galapagos NV Allocate Funds

R&D Spending: A Tale of Two Biotech Giants

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alkermes plc and Galapagos NV have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Galapagos NV consistently outpaced Alkermes plc, with R&D expenses peaking at over 500% higher in 2020. This trend highlights Galapagos NV's aggressive pursuit of new therapies, particularly in the mid-2010s when their spending surged by 96% from 2014 to 2018. In contrast, Alkermes plc's R&D spending saw a dramatic increase in 2022, reaching its highest point, which was nearly 50 times its 2014 expenditure. This shift suggests a strategic pivot towards innovation. As these companies navigate the evolving biotech landscape, their R&D allocations will continue to shape their competitive edge and market positioning.